Research trials have shown that combining Favezelimab and pembrolizumab exhibits effective anti-tumor activity, particularly in individuals with a Combined Positive Score (CPS) for PD-L1 ≥ 1 (Garralda et al., 2022). The gene discussed is CD274; the disease is neoplasm.